• Users Online: 131
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2018  |  Volume : 1  |  Issue : 3  |  Page : 104-110

YKL-40 in high-grade glioma: Prognostic value of protein versus mRNA expression


1 Department of Neurosurgery, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China
2 Department of Physiology, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei, China
3 Center for Evidence-based and Translational Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China
4 Department of Neurosurgery, Laboratory of Neuro-Oncology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China

Correspondence Address:
Dr. Zhi-Qiang Li
Department of Neurosurgery, Zhongnan Hospital, Wuhan University, Wuhan 430072, Hubei
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/glioma.glioma_16_18

Rights and Permissions

Background: YKL-40 has been reported to be associated with the prognosis of glioma patients. However, expression of YKL-40 was detected at protein or mRNA level in different studies. This may result in conclusion bias. This study is to investigate the prognostic value of increased YKL-40 protein versus mRNA expression in glioma patients. Methods: A comprehensive systematic search and review were performed using PubMed, EMBASE, and NKI databases to identify literature (published before May 1, 2018) that evaluated the association between YKL-40 and survival in glioma patients. Results: Thirteen relevant studies, involving 2139 patients, were included in this study. Elevated YKL-40 expression was associated with worse overall survival (OS) in glioma patients (hazard ratio [HR] = 1.44, 95% confidence interval [CI]: 1.27–1.63, P < 0.001), especially in high-grade glioma (anaplastic glioma: HR = 1.37, 95% CI: 1.09–1.74, P = 0.008; glioblastoma multiform: HR = 1.52, 95% CI: 1.33–1.73, P < 0.001). The increased YKL-40 protein level in serum (detected by ELISA) or in tumor tissues (detected by immunohistochemistry) was associated with worse OS (ELISA: HR = 1.43, 95% CI: 1.29–1.59, P < 0.001; immunohistochemistry: HR = 1.52, 95% CI: 1.20–1.93, P = 0.001). However, the association between elevated YKL-40 mRNA level (detected by real-time PCR) with worse OS was not significant (HR = 1.44, 95% CI: 0.73–2.83, P = 0.29, I2 = 68.3%). In addition when status of IDH1 mutation or/and O6-methylguanine-DNA methyltransferase promoter was incorporated as multivariate, increased expression level of YKL-40 was not associated with poorer survival (HR = 1.39, 95% CI: 0.99–1.93, P = 0.055). Conclusion: YKL-40 protein level, rather than mRNA level, may be a valuable biomarker to assess the prognosis in glioma patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3799    
    Printed217    
    Emailed0    
    PDF Downloaded361    
    Comments [Add]    
    Cited by others 4    

Recommend this journal